Premium
The Effect of Bidisomide (SC‐40230), a New Class Ia/Ib Antiarrhythmic Agent, on Defihrillation Energy Requirements in Dogs with Healed Myocardial Infarctions
Author(s) -
HACKETT AIMEE M.,
GARDINER PETER,
GARTHWAITE SUSAN M.
Publication year - 1993
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.1993.tb01583.x
Subject(s) - medicine , ventricle , qrs complex , cardiology , heart rate , defibrillation , hematocrit , blood pressure , placebo , myocardial infarction , saline , anesthesia , alternative medicine , pathology
Bidisomide is a Class Ia/Ib antiarrhythmic agent with activity against ventricular and supraventricular arrhythmias. The potential for bidisomide to increase defibrillation threshold (DFT) was tested in anesthetized dogs with healed left ventricular infards (≥ 10 days). Defibrillation patches were attached to each ventricle and shocks were delivered via an external cardioverter/defibrillator. Three groups were studied: placebo (saline), canine therapeutic bidisomide (TB, 2–5 μg/mL plasma concentration) and supratherapeutic bidisomide (STB, 6–14 μg/mL). Each animal received only one treatment. An abbreviated DFT curve was determined before and after treatment. Heart rate, blood pressure, PR, QRS, infarct size, and hematocrit were also measured be/ore and after treatment. DFT was significantly increased (average + 3 to +5 joules [J], P < 0.05) by TB and STB. TB (5/5) did not increase DFT beyond 40 J. In 6/7 experiments, STB did not increase DFT beyond 40 J. Placebo (n = 6) had no significant effect on DFT. Infarct size (x = 11% of the left ventricle) was not significantly different between groups. Heart rate and QRS were not significantly altered but blood pressure was significantly decreased (16%‐31% systolic, 29%‐45% diastolic) and hematocrit was significantly increased (19% to 25%) in oil groups. PR was significantly increased by STB only. Conclusion: therapeutic and supratherapeutic doses of bidisomide slightly but significantly increased DFT (3–5 J) in a canine infarcted heart model.